Clinical Trial Update: InterSEPT: In-Tunnel SeptRx European PFO Trial [NA]

View source ↗

Summary

An update on the InterSEPT European PFO trial by SeptRx, Inc. indicates the trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Defects
• Patent Foramen Ovale
• Septal Defects

Drugs mentioned

• SeptRx

Snippet

Sponsor: SeptRx, Inc. | Conditions: Foramen Ovale, Patent, Heart Defects, Congenital | NA | Status: UNKNOWN